Juno Pharmaceuticals Canada a Canadian specialty pharmaceutical company, announces that it has received approval from Health Canada to import eptifibatide solution for infusion and injection pursuant to Health Canada guidelines for exceptional imports and sales. Juno has acquired a six-month supply for immediate distribution across the Canadian market to help replenish dangerously low inventory.

Eptifibatide is prescribed to patients with certain types of acute coronary syndromes (diseases in which the flow of blood to the heart is reduced or blocked) when they are having special procedures to prevent blood clots from forming, such as placement of an intracoronary stent. The availability of this drug has been limited since October 2022, and over the past five months some hospitals have had to resort to alternative solutions to replace it. According to Thrombosis Canada , blood clots are responsible for one in four deaths each year in the country.

“Canada is faced with stock variations in different classes of drugs, whether it is cold and flu medication, antihistamines, painkillers or antibiotics. Eptifibatide is one of many drugs that Canadians have struggled to get hold of for months, says Greg LaMorre, Director, Supply Chain and Supplier Relations. As all stocks of this product are now sold out, this delivery comes at a critical time and will bring immediate relief to hospitals across the country. »

In the wake of the children's drug shortage that made headlines this winter, Juno's internal drug shortages division has imported pediatric amoxicillin, helping provide relief to more than 60,000 Canadian families so far . Juno remains focused on sourcing, registering and importing drugs from foreign countries to address domestic shortages.

“Canada's drug supply system has entrenched vulnerabilities,” said Mark Mantel, President and CEO of Juno. The stakes could not be higher for patients suffering from shortages, and this gravity and urgency must be reflected in the efforts of the manufacturing community to maintain a reliable supply for all Canadians. To avoid future shortages, global players will need to be encouraged to bring their products to the Canadian market. Going forward, investing in domestic production and supporting manufacturing facilities on Canadian soil should be a priority. »

About Juno Pharmaceuticals Canada

Juno Pharmaceuticals Canada specializes in the commercialization of high value-added complex generic and biosimilar products in the Canadian market. Juno's management team has decades of experience in the pharmaceutical industry as well as extensive experience in accelerating strategic growth through the identification of niche products and the disciplined creation of portfolios of robust products. Juno's global operations, an early member of the global Juno Pharmaceuticals group, span four continents and include more than 14 diverse pharmaceutical and medical device companies spanning Canada, the United Kingdom, the European Union , Australia and South Africa.

Contacts
Catherine Buteau
catherine.buteau@kaiserpartners.com
514-777-4183

 

Source:businesswire.com

Report Abuse